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Mammalian cells can acquire cholesterol through two tightly regulated pathways, namely de novo cholester- 
ol synthesis and receptor-mediated endocytosis of circulating low density lipoprotein (LDL). Malignant cells 
growing in vitro acquire choksteroi through both mechanisms but the quantitative importance of these 
pathways to a cancer growing in vivo is not known. Using the Lewis rat renal carcinoma model, this study 
measured the rate of cholesterol acquisition via both pathways in vivo in both normal and malignant renal 
tissue. In contrast to normal kidney, after malignant transformation, LDL-receptor activity disappeared 
entirely and the cancer acquired the cholesterol needed for growth by a S-fold increase in the rate of choles- 
terol synthesis. 
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1. INTRODUCTION 
Cholesterol is a necessary constituent of eucary- 
otic cell membranes and consequently elaborate 
regulatory mechanisms have evolved to ensure an 
adequate supply of sterol for new membrane syn- 
thesis [l]. A mammalian cell can potentially ac- 
quire cholesterol through 3 pathways 121. First, it 
can synthesize new cholesterol from acetyl-CoA 
via a tightly regulated pathway in which the forma- 
tion of mevalonic acid is the rate-limiting step. 
Second, it can take up cholesterol from circulating 
LDL through a receptor-mediated endocytotic 
process (receptor-dependent LDL uptake) that, in 
cultured cells at least, is regulated at the level of 
tr~sc~ption of the gene for the LDL receptor [3]. 
Finally, the tissue can acquire cholesterol from cir- 
culating LDL via a non-saturable, apparently un- 
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regulated, uptake process that does not depend 
upon specific LDL receptors (receptor-independent 
LDL uptake) [4f. In the live animal, the cells of 
even mature organs require at least some new 
sterol for maintenance of membranes and cell 
repair. After malignant ransformation even greater 
amounts of cholesterol may be required to support 
cell proliferation and growth of the tumor. Presum- 
ably such malignant cells could acquire cholesterol 
through any (or all) of these 3 pathways. Up to 
now, however, there have been no quantitative 
data available regarding the importance (or even 
the existence) of receptor-dependent LDL uptake 
in malignant issues in vivo. This study, therefore, 
measured the absolute rates at which both normal 
and m~i~~tly transformed renal tissue acquire 
cholesterol through each of these 3 pathways under 
in vivo conditions. The results show that normal 
kidney in the rat acquires cholesterol predominant- 
ly through receptor-dependent LDL uptake and 
has a low rate of sterol synthesis. After malignant 
tr~sformation, however, LDL-receptor activity 
disappears entirely and the cancer acquires the 
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cholesterol needed for growth by a 5-fold increase 
in the rate of cholesterol synthesis. 
2. MATERIALS AND METHODS 
The Wistar-Lewis rat renal adenocarcinorna [5] 
used in this study offered the major advantage of 
being homologous to the host (unlike, e.g., a 
human tumor transplanted into a nude mouse). 
Therefore, species pecific ligand-receptor interac- 
tions such as receptor-dependent LDL uptake 
could be accurately quantitated. Tumor tissue was 
obtained from a single tumor-bearing rat and cut 
into pieces weighing approx. 1 mg. Two of these 
pieces were then microsurgic~ly implanted beneath 
the renal capsule of 80 syngeneic Lewis recipient 
rats. After 5 weeks the tumor-bearing rats were 
divided into 2 groups. In one group, the rates of 
LDL clearance by both the renal tumor and the 
contralateral normal kidney, as well as the liver, 
were measured using a p~m~~ontinuous infusion 
of either [i4C]sucrose-labelled rat LDL [6,7] (total 
LDL clearance) or [i4C]sucrose-labelled methyl- 
human LDL (receptor-independent LDL clearance) 
[S]. With this method, the plasma specific activity 
of the labelled LDL is held constant for the 6 h in- 
fusion period so the label accumulates in tissues as 
a linear function of time. Thus, the tissue clearance 
(,&h per g) of LDL for all tissues can be measured 
and when multiplied by the plasma LDL concen- 
tration, the absolute rate of LDL-cholesterol entry 
into each tissue is obtained @g/h per g). The rat 
LDL probe measures total LDL clearance whereas 
the methylated-human LDL probe, which does not 
interact with the rat LDL receptor [7] measures 
receptor-independent LDL clearance. The second 
group was injected with 100 mCi [‘HIwater and 
killed 1 h later to measure absolute rates of choles- 
terol synthesis in the renal tumor, normal kidney 
and liver [9,10]. 
3. RESULTS 
3.1. Tumor growth and metabolic effects 
Throughout the 5 week period, the recipients ap- 
peared healthy and none died. From a weight of 2 
mg at implantation, the tumors grew to a mean 
weight of 1590 f 160 mg by 5 weeks. Only 2 of the 
80 recipients failed to show tumor growth. To ex- 
clude the possibility that the presence of the tumor 
might indir~tly alter, e.g. by suppressing food 
consumption, either the expression of LDL recep- 
tors or the rate of cholesterol synthesis in other 
tissues, the rates of total LDL uptake and choles- 
terol synthesis were measured in the liver and 
kidney of tumor-bearing rats and in sham-operated 
control rats. It was found that the presence of the 
tumor did not affect either process. Thus, a direct 
comparison of LDL uptake and cholesterol syn- 
thesis could be made between normal and malig- 
nantly transformed renal tissue in vivo in the same 
animal. 
3.2. Receptor-independent and receptor- 
dependent LDL transport by the tumor 
Total LDL clearance in the normal kidney oc- 
curred, as reported [4), at one-third the rate ob- 
served in the liver (table 1). The renal tumor, 
however, cleared LDL at only one-fifth the rate 
found in the normal kidney. Importantly, receptor- 
independent LDL clearance was essentially the 
same in the kidney and the renal tumor (table 1, 
Tabie 1 
Comparison of 3 pathways through which normal renal tissue, malignant renal tissue and liver acquire cholesterol 
Tissue LDL clearance 
&l/h per g) 
Absolute mass of cholesterol acquired via each 
pathway &l/h per g) 
Total Receptor- Receptor- Receptor- Receptor- De nova 
clearance independent dependent independent dependent synthesis 
clearance clearance LDL transport LDL transport 
Normal renal 31 f 1 5*1 26 f 1 0.7 f 0.1 4 f 0.1 0.9 f 0.1 
Malignant renal 6~1 65~ 1 0 1.0 * 0.1 0 4.1 f 0.4 
Liver 93 f 4 8il 85 f 4 1.2 f 0.1 12.8 + 0.6 48.4 + 3.9 
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column 2); thus, the decrease in total LDL clear- 
ance seen in the tumor resulted from complete loss 
of receptor-dependent LDL uptake by the malig- 
nant tissue (table 1, column 3). This loss is seen 
even more dramatically when these clearance values 
are expressed as absolute rates of LDL-cholesterol 
uptake and compared directly to the rates of total 
and receptor-independent LDL transport observed 
in the normal kidney of non-tumor-bearing control 
rats (fig. 1). As is apparent, the data obtained in the 
total LDL uptake 
l Normal renal +~ssue. 
receptor ,ndep?ndenf LDL uptake 
A thhqnont renai tissue, 
total LDL uptake 
Receptor Independent 
j ;k_y+--J 
5 10 15 20 25 
PLASMA LDL-CHOLESTEROL 
CONCENTRATION (mg,/dl) 
Fig.1. Total and receptor-independent LDL uptake in 
normal and malignant renal tissue. The kinetic curves 
show the rates of total and receptor-independent LDL- 
cholesterol uptake into the kidney as a function of the 
plasma LDL-cholesterol concentration in control rats 
without tumors. The lower curve, obtained using methyl- 
ated-human LDL, illustrates that receptor-independent 
LDL uptake by the kidney is a linear function of the 
plasma LDL concentration. In contrast, total LDL 
transport (upper curve) in the normal kidney shows a 
curvilinear relationship to the plasma LDL-cholesterol 
concentration. The difference between these 2 curves 
represents the magnitude of the receptor-dependent 
component of LDL transport in the normal kidney at 
any concentration of plasma LDL-cholesterol. Super- 
imposed upon these curves are the data obtained in the 
present study for homologous rat LDL uptake and 
methylated-human LDL uptake in both the kidney and 
malignant renal tumor obtained from the tumor-bearing 
animals. 
kidneys of tumor-bearing animals are superim- 
posable upon the standard kinetic curves for LDL 
transport in the kidney, i.e. the rate of receptor- 
independent LDL-cholesterol uptake equaled 
0.7 f: 0.1 pg/h per g while receptor-dependent up- 
take equaled 4.0 f 0.1 pg/h per g (table 1, columns 
4 and 5). In contrast, the renal tumor manifested 
no receptor-dependent LDL transport so that the 
uptake of homologous LDL and methylated-human 
LDL were essentially equal and, furthermore, both 
of these uptake rates fell on the curve defining the 
rate of receptor-independent LDL transport in the 
normal kidney (fig. 1). 
3.3. Cholesterol synthesis by the tumor 
As expected, the rates of incorporation of [3H] 
water in vivo into cholesterol were high in the liver 
(155Ok 125 nmol/h per g) and much lower in the 
kidney (30~5 nmol/h per g); however, the incor- 
poration rate in the renal tumor was nearly 5-fold 
higher (132 f 12 nmol/h per g) than the kidney. 
When these incorporation rates were converted to 
absolute rates of sterol synthesis, the tumor was 
found to synthesize 4.1 kO.4 /rg cholesterol/h per 
g while only 0.9 f 0.1 pg/h per g were synthesized 
in the normal kidney. Thus, as summarized in col- 
umns 4-6 of table 1, with the loss of receptor- 
dependent LDL transport, most of the sterol ac- 
quired by the tumor cells came from de novo syn- 
thesis rather than from the uptake of LDL-choles- 
terol. 
4. DISCUSSION 
While many malignant cells adapted to grow in 
vitro express LDL-receptor activity [l l-151, it has 
not been possible to measure in absolute terms 
whether this pathway is responsible for cholesterol 
acquisition in the malignant tumor in vivo. The 
data reported here were made possible by the 
development of techniques for quantitating the 
rates of receptor-dependent and receptor-indepen- 
dent LDL uptake and sterol synthesis under in vivo 
conditions [6-81 and clearly demonstrated that all 
receptor-dependent LDL-transport activity was 
lost after malignant ransformation of the kidney. 
This is similar to the situation seen in the WHHL 
rabbit that genetically lacks receptor-dependent 
LDL transport [ 161. In the kidney of normal rab- 
bits the rates of homologous and methylated- 
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human LDL clearance equal 11 and 3 pi/h per g, 
respectively, while in the kidney of the WHHL 
rabbit both of these LDL preparations are cleared 
by the kidney at 3 $fh per g 1171. Hence, the renal 
adenocarcinoma reported here in the rat behaves 
like the normal kidney of the receptor-deficient 
rabbit. 
The complete loss of LDL-receptor activity in 
vivo after malignant tr~sformation was unex- 
pected and runs counter to what would have been 
predicted on the basis of a variety of malignant 
cells growing in vitro [ 1 l- 151. The fact that recep- 
tor-independent LDL transport was not affected 
by transformation means that the loss of receptor- 
dependent LDL transport was not due to a change 
in capillary permeability within the tumor. If this 
loss of receptor activity is found to be a general 
characteristic of malignant issues in vivo, then the 
LDL-receptor mechanism cannot be utilized to 
deliver anti-tumor agents to primary or metastatic 
malignancies in vivo but, inhibition of cholesterol 
synthesis in the tumor coupled with a reduction in 
circulating plasma cholesterol levels could con- 
ceivably be utilized therapeutically to control 
tumor growth. 
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